Other News To Note
Friday, June 17, 2011
NovaBay Pharmaceuticals Inc., of Emeryville, Calif., regained worldwide rights to its topical Aganocide compounds for antibiotic-resistant eye, ear and sinus infections after Alcon Inc., of Huenenberg, Switzerland, terminated the companies' collaboration. NovaBay will receive a $2.97 million termination payment. Alcon completed a proof-of-concept trial of NVC-422 in viral conjunctivitis last fall.
Outside of the US
Part of Thomson Reuters
Note: our contact information has changed
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
© 2017 Thomson Reuters. Reproduction, reposting content is strictly prohibited.